Main features of microcytic anemias
. | Acquired conditions . | Inherited conditions . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
. | IDA . | ACD . | BT trait . | IRIDA . | AHMIO1 . | AHMIO2 . | EPP1/2 . | SIDBA1 . | SIDBA2 . | SIDBA3 . | ASAT . | Hypotransferrinemia . |
Genetic features | ||||||||||||
Causative gene(s) | — | — | HBB | TMPRSS6 | SLC11A2 | STEAP3 | FECH/CLPX | ALAS2 | SLC25A38 | GLRX5 | ABCB7 | TF |
Inheritance | — | — | AR | AR | AR | AD | AR/AD | XLR | AR | AR | XLR | AR |
Hematological and biochemical features | ||||||||||||
RBC | ↓ | ↓ | ↑ | ↓↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
Hb | ↓ | ↓ | = or ↓ | ↓ or ↓↓ | ↓↓ | ↓↓ | ↓ | ↓ | ↓↓ | ↓↓↓ (age dependent) | ↓ | ↓ |
MCV | ↓ | ↓ | ↓ | ↓↓ | ↓↓↓ | ↓ | ↓↓ | ↓ | ↓ | ↓↓ | ↓ | ↓↓ |
RDW | = | = or ↑ | = or ↑ | = | = | ↑ | = | = | ↑ | = | = | = |
Reticulocytes | ↓ | = or ↑ | = or ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
Tsat | ↓↓ | = | = | ↓↓ or ↓↓↓ | ↑↑ | ↑↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 100% |
Ferritin | = or ↓ | = | = | = or ↓ | ↑ | ↑ | = | = | = | = | = | = |
FEP | = or ↑ | = | = | ↑↑ | ↑ | = | ↑↑↑ | = or ↓ | = | = | = or ↓ | = |
Iron administration | ||||||||||||
Oral response | Yes | Unpredictable | No | No | No | — | No | No | — | No | No | No |
Intravenous response | Yes | Unpredictable | No | Yes (not long lasting) | No | — | No | No | — | No | No | No |
Suggested therapy | Oral iron supplement | Etiologic therapy (EPO, IV iron) | — | — | EPO | — | β-carotene | Vitamin B6 | — | Iron chelation | Vitamin B6 | Plasma; apotransferrin |
. | Acquired conditions . | Inherited conditions . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
. | IDA . | ACD . | BT trait . | IRIDA . | AHMIO1 . | AHMIO2 . | EPP1/2 . | SIDBA1 . | SIDBA2 . | SIDBA3 . | ASAT . | Hypotransferrinemia . |
Genetic features | ||||||||||||
Causative gene(s) | — | — | HBB | TMPRSS6 | SLC11A2 | STEAP3 | FECH/CLPX | ALAS2 | SLC25A38 | GLRX5 | ABCB7 | TF |
Inheritance | — | — | AR | AR | AR | AD | AR/AD | XLR | AR | AR | XLR | AR |
Hematological and biochemical features | ||||||||||||
RBC | ↓ | ↓ | ↑ | ↓↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
Hb | ↓ | ↓ | = or ↓ | ↓ or ↓↓ | ↓↓ | ↓↓ | ↓ | ↓ | ↓↓ | ↓↓↓ (age dependent) | ↓ | ↓ |
MCV | ↓ | ↓ | ↓ | ↓↓ | ↓↓↓ | ↓ | ↓↓ | ↓ | ↓ | ↓↓ | ↓ | ↓↓ |
RDW | = | = or ↑ | = or ↑ | = | = | ↑ | = | = | ↑ | = | = | = |
Reticulocytes | ↓ | = or ↑ | = or ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
Tsat | ↓↓ | = | = | ↓↓ or ↓↓↓ | ↑↑ | ↑↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 100% |
Ferritin | = or ↓ | = | = | = or ↓ | ↑ | ↑ | = | = | = | = | = | = |
FEP | = or ↑ | = | = | ↑↑ | ↑ | = | ↑↑↑ | = or ↓ | = | = | = or ↓ | = |
Iron administration | ||||||||||||
Oral response | Yes | Unpredictable | No | No | No | — | No | No | — | No | No | No |
Intravenous response | Yes | Unpredictable | No | Yes (not long lasting) | No | — | No | No | — | No | No | No |
Suggested therapy | Oral iron supplement | Etiologic therapy (EPO, IV iron) | — | — | EPO | — | β-carotene | Vitamin B6 | — | Iron chelation | Vitamin B6 | Plasma; apotransferrin |
ACD, anemia of chronic disease; AD, autosomal dominant; AHMIO, anemia, hypochromic microcytic, with iron overload; AR, autosomal recessive; ASAT, sideroblastic anemia with ataxia; BT, β-thalassemia; EPO, erythropoietin; EPP, erythropoietic protoporphyria; FEP, free erythrocyte porphyrin; SIDBA, sideroblastic anemia; XLR, X-linked recessive.